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Abstract
Background: To report the effect of intraoperative electron beam radiotherapy (IOERT) and external beam
radiotherapy (EBRT) in addition to surgery as well as to evaluate the role of resectable local recurrence for
long-term prognosis.
Methods: In 53 patients who underwent surgery for retroperitoneal soft tissue sarcoma (RSTS) from 2001 to 2014
prognostic and epidemiologic factors were reviewed retrospectively to analyze their impact on survival and recurrence.
Results: Twenty three patients (50%) had surgery plus radiotherapy, 23 (50%) had surgery only. Histology showed 73.
9% liposarcoma, 15.2% leiomyosarcoma and 6.5% pleomorphic undifferentiated sarcoma respectively. Low grade sarcoma
were observed in 52.2%, high grade sarcoma in 47.8%. The latter showed a trend towards a decreased
5-year survival rate (p = 0.125). Margin status was: R0: 60.9%, R1: 23.9%, R2: 15.2%; leading to significant changes in
5-year survival rate (R0: 77.6%; R1: 70.0%; R2: 42.9%; p = 0.03). Age younger than 55 years significantly improved
5-year survival rate (p = 0.039). Patients receiving resection of multiple sarcoma recurrence showed an almost identical
improved 5-year survival rate compared to patients without recurrence (no recurrence: 100.0%; single recurrence: 35.
0%; multiple recurrence: 91.7%; p = 0.001). Surgery plus radiotherapy led to significantly improved survival (p = 0.04).
Conclusions: There is a significant benefit in terms of 5-year survival after surgery plus some form of radiotherapy and
a good prognosis for patients when the recurrence from RSTS was resected. Age older than 55 years and incomplete
resection lowered 5-year survival rate significantly.
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Background
Soft-tissue sarcoma are rare tumor entities arising from
mesenchymal tissue. They account for less than 1% of all
solid tumors. About 85% of retroperitoneal tumors are
malignant and among those Retroperitoneal Soft Tissue
Sarcoma (RSTS) make about one third [1, 2]. Histologically
there are 3 predominant subtypes: liposarcoma (26–64.5%),
leiomyosarcoma (13.2–31%) and pleomorphic undifferenti-
ated sarcoma (PUS) (7–27%) [2–10].
Due to their anatomic origin the clinical presentation of
RSTS is typically inapparent and characterized by late
symptoms and a large tumor size at the time of diagnosis.
Consecutively vital structures and organs are already
involved or at risk which make the complete resection
difficult to achieve [3].
In current literature surgical resection is the mainstay
of treatment to achieve a long-term disease free survival
or cure. The rate of complete resection ranges from 41.8
to 76% [2–10]. Local recurrence rate is high even after
complete removal of the tumor. Among the treatment
modalities chemotherapy plays a minor role in adult
patients, whereas it has its benefits in bone and soft
tissue sarcoma (Ewing sarcoma, rhabdomyosarcoma,
osteosarcoma) that commonly occur in children [11].
The rationale for applying radiotherapy in addition to
surgery comes from small randomized controlled trials
showing evidence that radiotherapy enhances local con-
trol and resectability in soft tissue sarcoma of the limbs
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and RSTS without affecting survival [12–14]. In other
retrospective studies these positive effects on local con-
trol have been demonstrated in RSTS as well. Some
studies even propose a better overall survival [7, 8, 10,
15–17]. On the other hand opponents argue that the
value of radiotherapy remains questionable given that in
most studies no survival difference was detected [4, 18].
In this study prognostic and epidemiologic factors as
well as the 5-year-survival-rate of 53 patients after sur-
gery with or without radiotherapy for primary and recur-
rent RSTS was assessed.
Materials and methods
Approval of the local Ethical Committee as well as the
institutional review board was obtained before commen-
cing this study. In this series data from 53 patients who
underwent surgery under curative intention for RSTS
from 2001 to 2014 in a single institution (Department of
General- and Visceral Surgery, University of Freiburg)
were reviewed retrospectively. 7 patients were excluded
due to incomplete data or different tumor entity in post-
operative pathological report. For the remaining 46 pa-
tients with primary RSTS demographic characteristics,
clinicopathological parameters and treatment variables
were obtained in medical records, cancer registry entries,
radiology, pathology and operative reports.
The tumor characterization (TNM) was done in ac-
cordance with the seventh edition of the American Joint
Committee on Cancer (AJCC) staging system for soft
tissue sarcoma. Histopathologic subtypes were subdi-
vided into liposarcoma, leiomyosarcoma, pleomorphic
undifferentiated sarcoma (PUS) and others. The histo-
logic grading was performed according to the FNLCC
(Fédération Nationale des Centres de Lutte Contre le
Cancer) grading system whereupon FNLCC grade 1 and
2 were summed up as “low-grade-sarcoma” whereas
FNLCC grade 3 was regarded as “high-grade-sarcoma”.
Tumor size was documented by its greatest diameter
into the groups <5 cm, 5–10 cm, 10–20 cm, >20 cm.
Treatment variables analyzed included margin status,
local or visceral resection, chemotherapy and intraopera-
tive (IOERT) or perioperative radiotherapy: Margin sta-
tus was defined as R0 for microscopically tumor free
margins (complete resection), R1 for microscopically in-
filtrated tumor margins (incomplete resection) and R2
for macroscopically infiltrated tumor margins or residual
tumor at the operation site (incomplete resection).
Primary RSTS was defined as a tumor before treat-
ment. For statistical analysis no further differentiation
was made between local or distant recurrence. So re-
currence was defined as histologically proven recurrence
in close proximity or distant from the primary tumor site.
Tumor growth after R2 resected tumors was not included.
Perioperative morbidity was not assessed in this study.
Perioperative mortality was defined as death within 30 days
after surgery.
Surgical technique
Concerning our surgical approach we performed an
aggressive form of treatment established by Gronchi and
colleagues [8]. They could see lower rates of local and
distant recurrence after performing radical liberal en
bloc resection of all surrounding tissues and adjacent or-
gans in a proximity of 1 to 2 cm from the tumor surface.
Resection includes a locoregional peritonectomy which
is often accompanied by mainly removal of adjacent
organs which are fully or partially located in the retro-
peritoneum (kidneys, colon, pancreas, duodenum, psoas
muscle, diaphragm) when located close to the tumor.
With bigger tumors the extent of resection easily ex-
ceeds the sole resection of retroperitoneally located vis-
cera. Local resection was defined as resection of the
tumor with adjacent soft tissue but without visceral or-
gans. Visceral or multivisceral resection of the tumor
with one or more adjacent organs were summarized to
one group.
Additional therapy
The decision whether to receive radiotherapy/chemotherapy
or not was made by a multidisciplinary team of surgeons,
oncologists and radiotherapists without randomization in
accordance to the surrounding tissue and expected mor-
bidity due to radiation.
Chemotherapy
Chemotherapy neoadjuvant and/or adjuvant included
cisplatin, ifosfamide, doxorubicin, adriamycin, paclitaxel,
etoposid or epirubicin (VIC/VIP-E protocol).
Radiotherapy
Radiotherapy included either neoadjuvant external beam
radiotherapy (naEBRT), intraoperative (IOERT) or adju-
vant external beam radiotherapy (aEBRT). Sometimes
treatment included the combination of two or all three
modalities. For statistical analysis all patients receiving
some sort of radiotherapy whether neoadjuvant, intraoper-
ative or adjuvant were summarized to one group (S + RT).
An indication for IOERT was given if the tumor was
located in close proximity to irresectable structures and
if an R0 resection could not be anticipated safely prior
to operation. In uncertain cases operations were planned
with IOERT in stand-by.
All patients that were considered for IOERT had sur-
gery in a specific operating theatre with an integrated
linear accelerator (Siemens Mevatron ME®, Siemens
Healthcare GmbH, Erlangen, Germany). Prior to IOERT
our surgical team radically removed the tumor an adja-
cent organs if necessary, marked tumor margins and
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send the specimen to the pathologic for intraoperative
frozen section. In cases where the intraoperative situ-
ation evolved with adequate distance to the tumor and if
our pathologists confirmed intraoperatively tumor free
margins with a thick layer of healthy tissue in between
the indication for IOERT was abandoned in consent
with our attendant radiation therapists.
When receiving IOERT the resection site was ex-
plained to radiation therapist by the surgeon. After
receiving the results of the frozen section further re-
sections were made in case of R1 margins to achieve
the best possible resection status. The surgeon manu-
ally attached in correlation with size and form of the
tumor bed a suitable applicator to the OR-table and
aligned it to match the IOERT field with the tumor
cavity. For protecting uninvolved surrounding tissue
lead shields (5 mm) were applied. Attached to a mo-
bile operation table the patient was transferred under-
neath the linear accelerator and consecutively the
applicator was docked by a laser air-docking system
(100 cm focus-to-surface distance). The typical IOERT
dose was 15 Gy, using a electron energy of 6 MeV
(depth of 1.6 to 1.9 cm, 90% isodose level). Higher
radiation doses up to 20 Gy were applied due to sus-
pected R1 resection.
Before applying external beam radiation therapy
(EBRT) tumor volumes and organs at risk were defined
on a case to case basis from a planning CT scan or MRI
due to the individual characteristics of RSTS in
localization and tumor infiltration. EBRT was applied in
classic 4 field box technique (Elekta Synergy®, Elekta In-
strument AB Stockholm, Stockholm, Sweden) or in form
of volumetric modulated arc therapy (VMAT) (Rapid
Arc®, Varian Medical Systems, Palo Alto, CA, USA).
Treatment planning for volumetric-modulated arc
therapy was done with the EclipseTM treatment plan-
ning system (Varian Medical Systems, Palo Alto, CA,
USA). A 1–1.5 cm margin was added to the planning
target volume. Beam energy was 15 MeV.
The treatment planning system Oncentra MasterPlan®
(OTP, Nucletron BV (Elekta), Veenendaal, The Netherlands)
was used for 4 field box radiotherapy. A 1 cm margin
was added to the planning target volume, which was
generated from preinterventional MRI or CT-Scans.
Single beam energy was 6, 15 or18 MeV. Beams-eye
projections of the planning target volume were gener-
ated through multi-leaf collimators. The field controls
were done with cone beam CTs.
Statistical analysis
Statistical analysis was performed with SPSS® (Statistical
Package for Social Sciences, 22.0, Chicago, IL, USA).
Survival and Progression Free Survival (PFS) were calcu-
lated using the Kaplan–Meier method and univariate
analysis was performed with log-rank test and the
Gehan-Breslow-Wilcoxon method. In addition univariate
analysis was performed using chi-square test und Fish-
er’s exact test. Deaths were confirmed by our tumor
registry. There was no further analysis of the causes for
death. Patients with R2 margins were excluded from PFS
analysis as well as the analysis of recurrence due to their
persistent disease by definition. P values <0.05 were con-
sidered to be significant.
To determine independent prognostic factors Cox
proportional hazards regression model was used with
all factors that were significant (or close to signifi-
cance P < 0,1) in the univariate analysis.
Results
Demographic and tumor characteristics
Patient and tumor characteristics of the 46 patients with
RSTS included in this study are summarized in Table 1.
The median follow-up was 55.51 months (range 7–148
months).
Among those were 25 men (54.3%) and 21 women
(45.7%). The median age was 59.9 years (range: 33–83
years). 20 of the patients were younger than 55 years
(43.5%) while 26 of the patients exceeded 55 years of age
(56.5%).
Histology in 73.9% of the patients showed liposar-
coma, while 15.2% and 6.5% of the patients showed leio-
myosarcoma and pleomorphic undifferentiated sarcoma
(PUS) respectively. In 2 cases definitive histologic classi-
fication to one of those subtypes was not possible due to
poor tumor differentiation and was classified as malig-
nant pleomorphic mesenchymal tumors. Low-grade-sar-
coma was observed in 52.2% of patients while high-
grade-sarcoma was observed in 47.8% of patients.
In 4.3% of patients (n = 2) tumor size was <5 cm, in
15.2% (n = 7) tumor size was 5–10 cm, in 28.3% (n = 13)
tumor size was 10–20 cm and in 52.2% (n = 24) tumor
size exceeded 20 cm at primary diagnosis.
Median overall-survival for the 46 patients was not
yet reached. Of all patients 71.2% were alive after
5 years. The mean overall-survival was 112.1 months.
There was no significant influence on 5-year-survival
and PFS by gender, histological subtype or size of pri-
mary tumor.
Age
We could see significant benefits in survival of patients
younger than 55 years (89.59% vs. 63.1%; p = 0.039)
(Table 2). Influence of age on PFS could not be shown
(p = 0.740). Multivariate analysis showed a trend that age
could be an independent prognostic factor without
reaching significance (p = 0.121).
Hager et al. Radiation Oncology  (2017) 12:29 Page 3 of 9
Grading
High-grade-sarcoma showed a trend in decreased 5-year-
survival with 59.4% compared to low-grade-tumors with
85.6% (p = 0.125) (Table 2). There was no difference in
PFS (p = 0.753).
Surgery
Liberal en bloc resection of the adjacent tissues or or-
gans was performed after abdominal and retroperiton-
eal exploration. Altogether 99 surgical resections were
performed in 46 patients of whom 22 patients in part
with multiple tumor recurrence had repetitive surgery
ranging from 2 to 7 operations. After primary surgery
28 patients (60.9%) had a R0-resection, 11 patients
(23.9%) had a R1-resection and 7 patients (15.2%) had a
R2-resection. Consecutively patients with incomplete
resection had a higher rate of local or distant recur-
rence (81.8%, n = 9/11) compared to patients with
complete resection (46.4%, n = 13/28). 18.2% of patients
with incomplete resection had no recurrence detected
most likely due to early death within 1 year after sur-
gery, or due to short follow up time of approximately
1 year. Overall there was tumor recurrence in 22 pa-
tients (47.8%). Among those 22 patients 10 had a single
recurrence (SR, 21.7%) and 12 patients had multiple re-
currences (MR, 26.1%). In all 22 patients a second sur-
gical procedure was performed achieving a secondary
complete resection in 59.1%. In 31.8% (n = 7) of the
cases a R1-status and in 9.1% (n = 2) of the cases a R2-
status was attained.
In 39.1% of patients a local resection was possible, in
60.9% one or more contiguous organs or structures had
to be removed to achieve a R0-status (kidney n = 19,
psoas muscle n = 17, colon/rectum n = 16, small intes-
tine n = 11, parts of the abdominal wall n = 10, dia-
phragm n = 9, spleen n = 6, gallbladder n = 6, adrenal
gland n = 5, liver n = 5, partial resection of V. cava n =
5, pancreas n = 4, uterus n = 4, bladder n = 4, stomach
n = 2). Morbidity was not addressed in this study.
Among the 46 included patients there was no peri-
operative mortality. One patient excluded from the
study group due to missing data about primary tumor
characteristics died perioperatively. So mortality of the
whole collective of 53 patients was 1.9%.
Margin status
R-Status lead to significant changes in 5-year-survival,
with a R2-resection resulting in decreased survival (p =
0,03) (Table 2, Fig. 1). Multivariate analysis showed that
R-Status is an independent prognostic factor for survival
(p = 0.027) while PFS was statistically not significantly
influenced (p = 0,212).
Five-year-survival-rate and PFS was not influenced by
local resection compared to resections including in-
volved adjacent organs (Table 2). As long as recurrence
could be resected there was no influence on survival
provided that tumor recurrence was resected. This re-
sulted in an almost identical 5-year-survival of patients
with multiple recurrence compared to patients without
Table 1 Demographic, Tumor and Treatment Characteristics of
46 patients with RSTS who underwent surgical resection at the
Department of General- and Visceral Surgery, University of Freiburg
from 2001 to 2014
N (% of total)
Age (years)
< 55 20 (43.5%)
















< 5 cm 2 (4.3%)
5–10 cm 7 (15.2%)
10–20 cm 13 (28.3%)





Local resection 18 (29.1%)
Visceral resection 28 (60.9%)
Radiotherapy
Radiotherapy + surgery 23 (50%)






N number of patients
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recurrence (91.7% vs. 100.0%; p = 0.317), whereas 5-
year-survival-rate of patients with a single recurrence
was significantly worse in comparison (35.0%0; p =
0.001) (Table 2, Fig. 2). In patients where repeated re-
currences could be resected tumor biology was charac-
terized by slow tumor growth which led to a 5-year-
overall-survival of all patients. This was independent of
the grading of the sarcoma, since of 11 patients with
multiple recurrences, 5 patients had high-grade-sar-
coma (46.5%) and 6 patients had low-grade-sarcoma
(54.5%). Only one of these patients died within 5 years
– having a high-grade-sarcoma.
Radiotherapy
Twenty three (50%) patients received additional naEBRT,
IOERT or aEBRT in combination with their primary or
consecutive surgery. Patients receiving some form of
radiotherapy in combination with surgery (S + RT)
showed improved survival compared to patients receiv-
ing surgery only (SO) (82.3% vs. 58.6% p = 0,04) (Table 2,
Fig. 3). A subset analysis for comparison of the charac-
teristics of patients undergoing SO vs. S + RT showed
that there is no significant selection bias between these
two groups. By multivariate analysis overall-survival was
not affected by receiving radiotherapy (p = 0.251).
Table 2 Univariate analysis of prognostic factors influencing 5-year-survival-rate/Progression free survival in 46 patients with
retroperitoneal soft tissue sarcoma
All patients n = 46 After complete resection n = 39
Suvival rate Sarcoma recurrence
N Events (%) 5-YSR (%) SD P N Events (%) PFS (%) SD P
Age (years) 0.039 0.740
< 55 20 2 (10.0%) 89.5% 7.0 19 10 (52.6%) 37.3% 13.3
> 55 26 9 (34.6%) 63.1% 10.5 20 9 (45.0%) 27.7% 20.5
Gender 0.643 0.112
Male 25 5 (20.0%) 75% 10.2 21 8 (38.1%) 40.9% 16.3
Female 21 6 (28.6%) 66.8% 11.2 18 11 (61.1%) 26.6% 13.6
Presentation 0.001 0.753
No recurrence 17 0 (0%) 100% 0
Single recurrence 10 6 (60.0%) 40% 9.5
Multiple recurrence 12 1 (8.3%) 91.7% 8.0
Tumor Grade 0.125
High 22 8 (36.4%) 59.4% 11.3 17 9 (52.9%) 38.2% 14.5
Low 24 3 (12.5%) 85.6% 7.7 22 10 (45.5%) 29.0% 15.6
Tumor size 0.711 0.711
< 20 cm 22 5 (22.7%) 72.1% 10.9 19 10 (52.6%) 37.2% 14.0
> 20 cm 24 6 (25.0%) 70.9% 10.2 20 9 (45.0%) 30.1% 16.2
Resection status 0.03 0.212
R0 28 4 (14.3%) 77.6% 10.6 28 11 (39.3%) 45.4% 15.1
R1 11 3 (27.3%) 70.0% 14.5 11 8 (72.7%) 21.2% 13.2
R2 7 4 (57.1%) 42.9% 18.7
Local resection 18 3 (16.7%) 80.8% 9.9 0.267 13 6 (46.2%) 44.1% 16.6 0.582
Visceral resection 28 8 (28.6%) 65.2% 10.1 26 13 (50.0%) 26.5% 14.3
Radiotherapy 0.060 0.362
S + RT 23 3 (13.0%) 82.3% 9.8 22 9 (40.9%) 41.2% 18.3
SO 23 8 (34.8%) 58.6% 11.4 17 10 (58.8%) 26.8% 12.6
Chemotherapy 0.344 0.899
Yes 7 3 (42.6%) 57.1% 18.7 5 3 (60.0%) 40.0% 21.9
None 39 8 (20.5%) 74.1% 8.2 34 16 (47.1%) 28.7% 12.6
N number of patients, Events number of deaths and/or recurrences, 5-YSR 5 year survival rate, PFS progression free survival, SD standard deviation, P p-value, S +
RT surgery plus radiotherapy, SO surgery only
Hager et al. Radiation Oncology  (2017) 12:29 Page 5 of 9
In the group of 21 patients with recurrences 11 pa-
tients received radiotherapy. Among those patients all
had local recurrences only 2 patients developed distant
pulmonary metastasis in the later course of their disease.
The mean time until recurrence of the disease was
40.9 months in the surgery plus radiotherapy group vs
32.8 months in the surgery only group. So PFS was
slightly extended in the surgery plus radiotherapy group
without being significant (p = 0.362) which indirectly
suggests that there probably are indirect benefits in local
control. We did not perform exact analysis of local con-
trol because the timing and application of radiotherapy
was very heterogeneous and the individual effect of each
form of radiotherapy could not be differentiated further.
All 11 patients with tumor recurrences in the S + RT
group had local recurrences. In patients receiving some
form of EBRT +/− IOERT all local recurrences were
within the former tumor site or close to its margins
meaning that they were in field. Only 2 patients devel-
oped distant pulmonary metastasis in addition to their
local recurrence in the later course of their disease. For
patients who have received IOERT we cannot reproduce
the exact radiation fields due to the technique (as de-
scribed above) because the surgeon individually adapts a
suitable applicator to the intraoperative tumor bed with-
out prior image based planning of the exact field of radi-
ation. After IOERT and surgery the resection cavity
changes in shape and size after surgically closing the
wound. So the postoperative correlation if a loco
regional recurrence is exactly in field or probably not is
difficult to do.
Chemotherapy
Eight patients (20%) received neoadjuvant and/or
adjuvant chemotherapy, including cisplatin, ifosfamide,
doxorubicin, adriamycin, paclitaxel, etoposid and
epirubicin (VIC/VIP-E protocol). Receiving some form
of chemotherapy in combination with surgery had no
influence on overall survival (p = 0.344) and on PFS
(p = 0.899) (Table 2).
Discussion
A major issue of studies concerning the treatment of
retroperitoneal sarcoma is that randomized controlled
studies are rare due to small patient numbers in general.
Fig. 1 Sarcoma specific 5 year-survival of 46 patients with RSTS who
underwent surgical resection divided by R-status (R0-margin [yellow]
77.6% vs. R1-margin [blue] 70.0% vs. R2-margin [red] 42.9%; p = 0.03)
Fig. 2 Sarcoma specific 5 year-survival of 46 patients with RSTS who
underwent surgical resection divided by type of recurrence (no
recurrence [yellow] 100.0% vs. single recurrence [red] 40.0% vs.
multiple recurrences [blue] 91.7%, p = 0.001)
Fig. 3 Sarcoma specific 5-year-survival of 46 patients with RSTS who
underwent surgical resection with or without radiotherapy (SO = surgery
only [red] 58.6% vs. S + RT = surgery plus radiotherapy [blue] 82.3%,
p= 0.043)
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Accordingly most data – as well as in this study - was
collected in retrospective surveys. Therefore the limita-
tions of retrospective study design do apply for most
findings.
Unlike most solid organ derived tumors of visceral
cavity the individual prognosis of RSTS is directly linked
to the site of origin of the primary tumor and its sur-
roundings. Id est the extent of an indicated surgical re-
section is not standardized among individual cases and
f.e. a tumor of identical histology and size is treated
differently due to its origin and adjacent vital structures.
Related to this consideration established prognostic
factors for overall survival in patients with retroperiton-
eal sarcoma comprise margin status, grading, histological
subtype and tumor size [4, 5, 14, 19, 20].
In larger studies high grade tumors are related to a
poorer 5-year-survival-rate [2, 3, 5, 9, 19]. We could not
reproduce this effect significantly. This is maybe due to
small patient numbers in this study. In all 46 patients
high-grade-sarcoma showed a trend in decreased 5-year-
survival with 59.4% compared to low-grade-tumors with
85.6% (p = 0.125). There was no difference in PFS (p =
0.753). Either gender or tumor size did prove to be signifi-
cant prognostic factors for survival. Interestingly we found
age younger than 55 years to be significantly beneficial for
5-year-survival in the univariate analysis. Reasons for this
observation remain notional. There was no further ana-
lysis of the causes for death. So no conclusions whether
death was sarcoma related or not could be made. A lack
of comorbidities in the group “age <55 years” could be a
possible explanation. In a subset analysis there was no
selection bias between these two groups.
Surgery
The complete surgical resection is the main treatment
modality in patients with retroperitoneal sarcoma [3, 9].
With large tumor size at the time of diagnosis and its mar-
gins in close proximity to vital structure, complete surgical
resection is a challenging goal to achieve. The rate of
negative resection margins ranges from 41.8 to 76%,
which then result in improved survival [2–10]. In our ana-
lysis margin status proved to be an independent prognos-
tic factor for 5-year-survival-rate within the univariate as
well as multivariate analysis (p = 0,03/p = 0,027).
In our cohort we could achieve a complete resection
in 60.9% of our patients. Although complete resection
can be achieved in most cases, the rate of recurrence is
high and varies between 28 and 77% [5, 20]. In our study
we could see a 5-year-PFS of only 34.4% ± 10.8%. Despite
these discouraging results in PFS we achieved a second-
ary margin free resection in 59.1% (n = 13) of the 22 pa-
tients with tumor recurrence, similar to Gholami et al.
and Van Dalen et al. who demonstrated that a secondary
complete resection in patients with sarcoma recurrence
could be achieved in most cases resulting in resection
rates comparable to those of primary surgery. With sub-
sequent surgery a disease-free-status was achieved and
survival was improved [19, 21].
In low-grade-sarcoma we could see most patients with
a long term survival exceeding the 5-year-range by far
even if a complete resection has not been achieved.
Interestingly we found in our data that survival of
patients with multiple recurrences and patients without
recurrence was almost identical resulting in long term
survival for individual patients with multiple recurrences
throughout the whole observation period. There was no
significant selection bias concerning tumor grading
within this subgroup.
Congruently Van Dalen et al. could see that in contrast
to patients with high-grade-sarcoma a large proportion
of patients with low-grade-tumors remained alive for a
long period. Loco regional and slower growth of low-
grade-recurrences as well as better opportunities for
repetitive surgical treatment were possible explanations
for these findings [22]. Furthermore Petersen et. al.
could show that neither primary vs. recurrent status nor
tumor grade had a significant impact on survival [23].
A possible explanation for the decreased 5-year-
survival in our patients with a single resected recurrence
is the higher percentage of cases with leiomyosarcoma,
PUS and one malignant pleomorphic mesenchymal tu-
mors within this subgroup (no recurrence: 23.5% (n = 4/
17); multiple recurrence: 25.0% (n = 3/12), single recur-
rence: 40.0% (n = 4/10)) which are associated with an re-
duced 5 year-survival-rate [9]. In addition the two cases
where a secondary complete resection could not be
achieved pertain to this subgroup.
Frankly, there is evidence that the prognosis for
patients with tumor recurrence that is resectable is not
necessarily worse than in patients without recurrence.
Regarding this we think that subsequent surgery even
with multiple recurrences over the course of time pro-
vides a solid basis for long term survival especially in
low-grade-RSTS. Consistent with findings of Colleagues
at the Stanford University and the University of Heidel-
berg we could see that treatment of local recurrences,
even on multiple occasions, is effectively possible by
subsequent surgical resection [19, 24].
Radiotherapy
In literature the benefits of radiotherapy in addition to
surgery are controversially discussed. Although there is a
consensus among most studies that surgery in addition
to EBRT with or without IOERT lead to better outcomes
regarding local control in cases with primary and recur-
rent disease or in patients with microscopically incom-
plete resection as well as reduced risk of sarcoma related
death [5, 8, 10, 23, 25–27], there was few data of
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improved influence on survival [15, 17, 23, 26]. There-
fore some colleagues argued that the value of radiother-
apy remains questionable particularly if it comes at the
expense of toxic complications [4, 18]. Strong arguments
for the impact of EBRT on survival are given by a recent
study of Nussbaum and colleagues: It is the largest study
to date including over 9000 patients analyzed retrospect-
ively for the effect of neoadjuvant or adjuvant radiother-
apy on overall survival in patients with RSTS. Both
neoadjuvant and adjuvant radiotherapy were associated
with improved 5-year-survival compared with surgery
only (neoadjuvant: 62% versus 54%, p < 0 · 0001; adju-
vant: 60% versus 52%, p < 0 · 0001) [28].
Severe toxic complications related to radiation after
treating RSTS with EBRT and/or IOERT range from 10
to 37%. They include neuropathy, grade 3 and 4 enter-
itis, hydronephrosis, gastrointestinal fistula, gastric out-
let obstruction, bowel obstruction, vaginal fistula, wound
complications, abscesses and bleeding [25].
In our study we could see significant benefits on 5-year-
survival after S + RT. As mentioned above there was no
randomization, which could have had an influence on sur-
vival as well as on the risk of recurrence. However patients
receiving S + RT showed improved survival without affect-
ing PFS in the univariate analysis (S + RT 82.3%, SO
58.6%; p = 0,04). But it was not an independent prognostic
factor in multivariate analysis (p = 0.251). Our findings are
congruent with a recent Swedish study as well as with the
study of Pierie et al.. They did not only show an improved
rate of local control but also significant advantages in 5-
year-overall-survival [15, 26].
Conclusions
Complete surgical resection is an important prognostic
variable that can be performed in patients with primary
and recurrent sarcoma. Our results show that there is an
improved survival even with multiple resections as well
as in combination with radiotherapy. To provide evi-
dence in treatment recommendations, larger multi-
centric or multinational, randomized, controlled trials
are imperatively required.
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